SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is generating significant social media buzz as traders debate its potential as a high-growth Layer-1 alternative to Solana, with many highlighting its integration into institutional products and recent developments within its ecosystem. Community discussions are split between bullish sentiment fueled by institutional accumulation and skepticism from those wary of market volatility and recent price fluctuations.

StupidCoin

StupidCoin is gaining significant traction within the Solana ecosystem as traders rally behind its active community-led development and viral marketing efforts. Enthusiasts are highlighting the project's recent growth, community collaborations, and ecosystem integrations as key drivers for heightened market interest.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The community is actively debating the potential for a breakout or consolidation phase as $PEPE trends alongside broader meme coin volatility. Traders are expressing mixed sentiments, with some focusing on long-term accumulation strategies during pullbacks while others remain skeptical about the coin's price stability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive pre-BLA meeting with the FDA, which aligned on the submission path and label strategy for sonelokimab in hidradenitis suppurativa. Community discussion is focused on the upcoming VELA 52-week durability data and the potential for a favorable BLA submission in late 2026, with investors actively debating the competitive positioning against existing treatments and anticipating a potential price re-rating.

Got that dog in you? - Fueled by a mantra of tokenized self-belief, doginme is representative of the community's collective efforts to embrace and embolden that dog in them. doginme stands for knowing yourself and having that unshakable drive to keep pushing forward. doginme was originally launched in February 2024 when the Farcaster founder was asked if he owned a dog, to which he replied affirmatively: "no but I got that dog in me"

doginme

DOGINME is trending as the community rallies around its unique 'tokenized self-belief' narrative, emphasizing grit and holding conviction during market volatility. Enthusiasts are actively highlighting the project's growth on the Base chain and speculating on potential exchange listings, with many members bonding over the core 'I got that dog in me' spirit.

eCash (XEC) is a Layer-1 digital cash network, developed by Bitcoin ABC. It was created on Nov 15th, 2020, and has since distinguished itself from its predecessors and other Bitcoin clients by integrating the breakthrough Avalanche consensus with its core proof-of-work (PoW) layer, extending its security and fundamental capabilities.  This Nakamoto/Avalanche hybrid consensus integration gives it unique properties for a Bitcoin-like chain, such as instant transaction finality, staking rewards, extensibility through subnets, and flexible protocol governance.  The development roadmap is set with three main goals: Scaling transaction throughput from ~100 tps to more than 5.000.000 tps Improving the payment experience with a less than 3 second transaction finality time Extending the protocol and establishing fork-free upgrades, allowing for more rapid, iterative development

eCash

eCash (XEC) is seeing significant community engagement as the network prepares for the November 15th Avalanche Pre-Consensus upgrade, which aims to deliver instant transaction finality. Builders and stakers are actively discussing these infrastructure milestones and the ongoing expansion of the eCash ecosystem.

Honda Motor Co., Ltd. engages in the manufacture and sale of automobiles, motorcycles, and power products. It operates through the following segments: Automobile, Motorcycle, Financial Services, and Power Product and Other Businesses. The Automobile segment manufactures and sells automobiles and related accessories. The Motorcycle segment handles all-terrain vehicles, motorcycle business, and related parts. The Financial Services segment provides financial and insurance services. The Power Product and Other Businesses segment offers power products and relevant parts. The company was founded by Soichiro Honda on September 24, 1948 and is headquartered in Tokyo, Japan.

Honda Motor - ADR

Honda Motor Co., Ltd.

Honda is experiencing significant volatility as the company grapples with an abrupt cancellation of its AFEELA EV joint venture with Sony and a massive writedown of its electric vehicle strategy. Community sentiment is mixed, with some investors focusing on the company's long-term reliability and value in hybrid markets, while others express frustration over its lagging pace in the global EV race compared to Chinese competitors.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following the announcement of a pivotal Phase 3 design for its lead drug candidate, CAD-1005, aimed at treating heparin-induced thrombocytopenia. While some investors are optimistic about the upcoming trial path and orphan drug designation, the community is currently debating the stock's volatility and widespread skepticism surrounding the heavy automated bot activity on discussion boards.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative momentum as investors rotate into IoT and Japanese-focused blockchain projects, while long-term supporters remain focused on ecosystem expansion and technical breakout patterns despite mixed sentiment. The community continues to debate the project's long-term utility versus its history of volatility, with many users actively accumulating positions in anticipation of potential future developments.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is capturing community attention as investors debate its potential as a high-speed institutional settlement layer, driven by speculation over pending partnerships and upcoming infrastructure milestones. While some community members are actively accumulating based on the project's technological claims, others are expressing frustration over stagnant price action and the repetitive promotional activity surrounding the token.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Houte Hans Van Sells 14,055 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 14,055 shares of the company's stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of...

Houte Hans Van Sells 2,388 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 2,388 shares of the company's stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an...

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fifteen analysts that are currently covering the firm, Marketbeat Ratings...

Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,388 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 2,388 shares of the firm's stock in a transaction dated Thursday, April 30th. The shares were sold at an average price...

Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 3,214 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 3,214 shares of Nurix Therapeutics stock in a transaction dated Thursday, April 30th. The stock was sold at an...

Pictet Asset Management Holding SA Acquires 1,487,060 Shares of Nurix Therapeutics, Inc. $NRIX

Pictet Asset Management Holding SA lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 75.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,467,600 shares of the company's...

Nurix Therapeutics (NASDAQ:NRIX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued a "buy" rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Monday...

Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX)

Needham & Company LLC reiterated a "buy" rating and issued a $26.00 price objective on shares of Nurix Therapeutics in a research note on Thursday...

Sumitomo Mitsui Trust Group Inc. Sells 266,925 Shares of Nurix Therapeutics, Inc. $NRIX

Sumitomo Mitsui Trust Group Inc. trimmed its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1...

Q2 EPS Estimate for Nurix Therapeutics Lifted by Analyst

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - HC Wainwright raised their Q2 2026 earnings estimates for shares of Nurix Therapeutics in a report issued on Friday, April 10th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.73) per share for the quarter, up from t...

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Current Price	$16.52
Prev Close	$16.28
Open	$16.29
Dividend Yield	0.00%
50-Day Moving Average	$15.94
Beta	1.62
Avg. Volume	1.07M
PE Ratio	-5.23

52-Week High	$22.50
52-Week Low	$8.20
Market Capitalization	$1.71B
EPS (Annual)	-$3.05
Price to Book	3.55
Revenue Per Employee	$264,921.14

NRIX
Nurix Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NRIX News

NRIXNurix Therapeutics Inc